Last reviewed · How we verify
Polyethylene glycol / Ascorbic acid
Polyethylene glycol acts as an osmotic laxative while ascorbic acid provides antioxidant support and enhances bowel cleansing efficacy.
Polyethylene glycol acts as an osmotic laxative while ascorbic acid provides antioxidant support and enhances bowel cleansing efficacy. Used for Bowel preparation prior to colonoscopy or other gastrointestinal procedures.
At a glance
| Generic name | Polyethylene glycol / Ascorbic acid |
|---|---|
| Sponsor | Tomas Bata Hospital, Czech Republic |
| Drug class | Osmotic laxative with antioxidant supplement |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Polyethylene glycol (PEG) is a non-absorbable osmotic agent that draws water into the intestinal lumen, promoting bowel evacuation without significant fluid or electrolyte loss. Ascorbic acid (vitamin C) functions as an antioxidant and may enhance the cleansing properties of the preparation. This combination is typically used for bowel preparation prior to diagnostic or therapeutic procedures.
Approved indications
- Bowel preparation prior to colonoscopy or other gastrointestinal procedures
Common side effects
- Nausea
- Abdominal discomfort
- Bloating
- Vomiting
Key clinical trials
- PEG-Asc Vs. SPMC for Bowel Preparation in Capsule-based Procedures (NA)
- Effect of Low-volume (1L) vs Intermediate-volume (2L) Bowel Preparation on Cost-effectiveness and Quality of Life (NA)
- A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy (PHASE4)
- Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure (PHASE3)
- Artificial Intelligence and Bowel Cleansing Quality
- Patient and Colonoscopy Cleansing Quality Agreement
- Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia
- Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: